Treatment of Peripheral Precocious Puberty.

Abstract

There are many etiologies of peripheral precocious puberty (PPP) with diverse manifestations resulting from exposure to androgens, estrogens, or both. The clinical presentation depends on the underlying process and may be acute or gradual. The primary goals of therapy are to halt pubertal development and restore sex steroids to prepubertal values. Attenuation of linear growth velocity and rate of skeletal maturation in order to maximize height potential are additional considerations for many patients. McCune-Albright syndrome (MAS) and familial male-limited precocious puberty (FMPP) represent rare causes of PPP that arise from activating mutations in GNAS1 and the LH receptor gene, respectively. Several different therapeutic approaches have been investigated for both conditions with variable success. Experience to date suggests that the ideal therapy for precocious puberty secondary to MAS in girls remains elusive. In contrast, while the number of treated patients remains small, several successful therapeutic options for FMPP are available.

• Authors: Melissa Schoelwer, Erica A Eugster
• Journal: Endocrine development (Endocr Dev) Vol. 29 Pg. 230-9 ( 2016) ISSN: 1662-2979 [Electronic] Switzerland
• PMID: 26680582 (Publication Type: Journal Article, Review)
• Copyright: © 2016 S. Karger AG, Basel.

Topics

• Adolescent
• Female
• Fibrous Dysplasia, Polyostotic (genetics, therapy)
• Humans
• Male
• Puberty, Precocious (drug therapy, etiology, genetics, therapy)